BMS-955176

BMS-955176

BMS-955176

Chemical compound

BMS-955176 is an experimental second generation HIV maturation inhibitor under development by Bristol-Myers Squibb for use in the treatment of HIV infection. By blocking the maturation of the virus, it prevents viral reproduction in host CD4+ T cells.[1] First generation maturation inhibitors such as bevirimat were ineffective against some naturally occurring changes (polymorphisms) in the Gag protease polyprotein; BMS-955176 has been selected to better tolerate gag polymorphisms.[2][3]

Quick Facts Legal status, Identifiers ...

Studies

Results of a phase 2a trial of BMS-955176 was reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI).[4] Investigators concluded that the drug was well tolerated and effective against HIV, including strains with gag polymorphisms.[4][5]

It appears that development of BMS-955176 has been terminated.[6]

See also

References

  1. [1]
    "BMS Maturation Inhibitor Is Potent Against HIV in Early Trial". 25 February 2015. Archived from the original on 23 July 2015. Retrieved 22 July 2015.
  2. [2]
    "CROI2015: New HIV maturation inhibitor BMS-955176 appears more potent than earlier beviramat - Project Inform".
  3. [3]
    Wang D, Lu W, Li F (November 2015). "Pharmacological intervention of HIV-1 maturation". Acta Pharmaceutica Sinica B. 5 (6): 493–9. doi:10.1016/j.apsb.2015.05.004. PMC 4675807. PMID 26713265.
  4. [4]
    "Antiviral Activity/Safety of a Second-Generation HIV-1 Maturation Inhibitor | CROI Conference". www.croiconference.org. Retrieved 2016-01-01.
  5. [5]
    "HIV maturation inhibitor BMS-955176 looks promising in early study". www.aidsmap.com. Retrieved 2016-01-01.
  6. [6]
    "GSK Discontinues Development of Maturation Inhibitor BMS-955176".
Share this article:

This article uses material from the Wikipedia article BMS-955176, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.